In more recent studies, QDs conjugated to the single variable domain of anti‐HER2 antibodies or the novel near‐infrared QDs bioconjugated to anti‐HER2 antibodies were successfully used for immunolabeling breast cancer cells 19, 20. This evidence concerns the gene ERBB2 and breast cancer.